Battle of Ideas

We should pay kidney donors

A steelman map of the public fight over kidney donors — arguments for and against, with sources and assumptions.

AI-generated · paired steelman agents · independently red-teamed · Pass-1 source spot-checks only · framing-fidelity not independently verified · single model family

Paying living kidney donors for the organ itself — not only travel and lost wages. Waitlists worldwide; Iran is one legal paid program, not the whole story. Paying expenses only, without buying the kidney, is a third camp the two columns do not settle. Not livers, hearts, or dead bodies.

AGAINST 8

no further strong arguments at this depth

FOR 8

no further strong arguments at this depth

People also ask

Questions people actually type. The two columns above are the cases — open a card for sources, assumptions, and counters.

Should we pay kidney donors?

Can you be paid to donate a kidney?

Is paid organ donation legal?

Paid organ donation pros and cons

How much does a kidney donor get paid?

Iran kidney donation system

Kidney transplant waiting list

Paid organ donation the case against

Ordering within each column: strongest first — validation tier, then source quality, then representativeness.

AGAINST · We should pay kidney donors
Empirical — moderateP1

Paid donors would not be the same people as today's screened altruists

Muzaale et al. (JAMA, 2014) already find higher 15-year ESRD in donors than in matched healthy nondonors, and a much higher absolute risk in Black donors. Segev's perioperative mortality is low in US registry altruists. AGAINST does not deny those papers. It denies the leap: that a paid cohort, poorer, more likely to hide hypertension or diabetes to pass screening, with less lifelong follow-up, will look like that cohort. Mjøen et al. (Kidney International, 2014) found survival curves of Norwegian donors and controls diverging after 5–10 years — a reminder that 'no extra death' in short US follow-up is not a lifetime warranty. A government cheque large enough to clear a list is large enough to be the best bad option in a household crisis. That is the consent problem and the medical-quality problem in one. FOR's cost-benefit (Held $45,000) prices a statistical life. It does not price a shift in who stands on the table. The third camp — pay lost wages and travel only (NLDAC) — exists because even reimbursement people can see the line. Crossing it to buy the organ is the claim AGAINST is refusing.

Key assumptions

  • Selection on poverty would worsen average donor health enough to matter clinically partial
  • Screening cannot reliably keep a paid pool as healthy as today's unpaid pool partial

Red team — the strongest counters

Payment can buy stricter screening, not looser

A state monopsony can afford tests altruistic programs ration. Hideable disease is a reason for better work-up, not for banning the only incentive that creates non-relative donors. Perioperative mortality fell in the unpaid pool as technique improved — that trajectory is not owned by altruism.

Mjøen is one country; the waitlist is thousands of deaths a year

Norwegian long-term divergence is a flag, not a worldwide rate. Even Muzaale's extra lifetime ESRD (90 vs 14 per 10,000) is a different order from 3,743 US waitlist deaths in a single year. Refusing payment to avoid a rare donor ESRD accepts a common recipient death.

Sources

  • Risk of End-Stage Renal Disease Following Live Kidney Donation Muzaale et al., JAMA 2014. 15-year ESRD 30.8 vs 3.9 per 10,000; Black donors 74.7. Pass-1: JAMA exists. AGAINST uses the paper's own risk gradient, not a new number. P1 checked
  • Long-term risks for kidney donors Mjøen et al., Kidney International 2014. Norwegian donors vs controls: mortality curves diverge after 5–10 years. Pass-1: KI page exists. One country, longer follow-up than many US papers — not a meta-analysis. P1 checked

Confidence, decomposed

Logical validity●●●●○
Premise support●●●○○
Representativeness●●●●○
Source quality●●●●●

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

AGAINST · We should pay kidney donors
Empirical — moderateP1

Iran did not 'eliminate the waiting list' — and its paid donors are the caution, not the brochure

Ghods and Savaj (2006) are the source of 'waiting list completely eliminated by 1999.' Behrooz Broumand, a former president of the Iranian Society of Nephrology, told the BMJ that it depends how you define waiting list. A later clinical paper (PMC 10514748) is blunter: there are in practice two lists — one for recipients, one for donors — and you do not wait if you can pay. Mahdavi-Mazdeh (Kidney International, 2012) called missing long-term donor follow-up the model's Achilles heel. KI Reports (2025) describes an official 800 million IRR gift (~US $1,400 in their conversion) plus an unofficial recipient payment 'typically several times higher,' with a patient-advocacy group filling gaps for those who cannot afford the extra. A 2024 field study in the European Economic Review can still write that Iran 'eliminated' the list — that is how a factoid travels. AGAINST's load-bearing point is not that zero extra transplants happened. It is that the one national experiment FOR wants to cite does not show a clean, equal, well-followed donor population. It shows a legal channel that still runs on extra cash and still fails the people who cannot pay. Exporting that, with better branding, is not a solution to a shortage. It is a decision about who the shortage is allowed to land on.

Key assumptions

  • Iranian clinicians disputing 'elimination' are describing the same list Ghods counted, not a different bureaucratic object partial
  • Unofficial top-ups are inherent to paying for kidneys, not a local enforcement failure partial

Red team — the strongest counters

A messy program that transplants is still more kidneys than a clean ban

Even if 'eliminated' is a definitional trick, Iran moved a large share of ESRD patients onto grafts from living unrelated donors. Contesting the slogan does not put those people back on dialysis. Copy the match organisation and the posted gift; do not copy the side payment.

Achilles-heel follow-up is a reason to build a registry, not to keep the price at zero

Mahdavi-Mazdeh named the missing registry as the model's flaw. That is a software patch: mandatory lifelong cover, as FOR already grants. Using Iran's record-keeping failure as a veto on payment anywhere treats a log problem as a metaphysics problem.

Sources

Confidence, decomposed

Logical validity●●●●○
Premise support●●●●○
Representativeness●●●●●
Source quality●●●●○

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

AGAINST · We should pay kidney donors
Empirical — moderateP1

Vendors regret it, stay poor, and miss the follow-up the brochure promised

Javaad Zargooshi (Journal of Urology, 2001a and 2001b) interviewed 300 Iranian kidney vendors a median of 61 months after sale, plus 100 controls who had nephrectomy for disease. Poverty kept 79% from follow-up visits. Employment was worse for 65%. Families strongly disagreed in 68% of cases; 43% were rejected; 73% had more marital conflict, including 21% who divorced. Seventy percent felt isolated; 71% had severe new depression; 60% anxiety. Eighty-five percent said they would definitely not vend again; 76% would tell others not to 'repeat their error.' Half would give more than ten years of life to have the kidney back. SF-36 scores were worse than controls on every scale. A later interview study (Fallah and others, International Urology and Nephrology) found 68% felt pressure from poverty or family, 84% feared stigma, even when they said they had not been physically coerced. AGAINST's load-bearing use: this is not a black-market horror from a country that bans payment. It is the legal system FOR wants to cite. A cheque that does not clear the vendor's debt, and a clinic they cannot afford to attend, is not a regulated success. It is how a price on a kidney actually feels from the table.

Key assumptions

  • Zargooshi's Kermanshah sample still describes later Iranian cohorts, not only the 1990s partial
  • A rich-country posted price plus lifelong insurance would not produce the same regret partial

Red team — the strongest counters

A 2001 clinic sample is not a 2026 national registry

Zargooshi's donors often predate later Iranian rules. Fallah's later interviews are smaller. Using 85% regret as the last word on any legal price is exporting one city's wound. A rich-country insurance wrap is a different object.

Regret after an irreversible act is not unique to payment

Unpaid related donors also regret, divorce, and drop out of follow-up. AGAINST owes a comparison, not only a vendor questionnaire. Waitlist death is also irreversible, and those people are not interviewed in JU.

Sources

Confidence, decomposed

Logical validity●●●●○
Premise support●●●●○
Representativeness●●●●●
Source quality●●●●○

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

AGAINST · We should pay kidney donors
Logically validP1

A kidney is not a spare part the poor should have to sell

The Declaration of Istanbul (Lancet, 2008; 2018 update) defines transplant commercialism as treating an organ as a commodity, including by buying or selling it. It says the poor who sell are being exploited, whether by richer people at home or by transplant tourists, and that the success of transplantation does not justify victimising the world's poor as the source of organs for the rich. More than 135 medical societies and governments endorsed it. WHO Guiding Principles have said the same family of things for decades: no payment that can be a gateway to trafficking. AGAINST does not need to pretend every cash transfer is a back-alley theft. The steelman is that 'consent' under debt is not the same act as an altruistic gift. Iran Open Data (2026) describes Telegram ads from people selling a kidney 'to survive,' official gifts around a thousand dollars, unofficial prices many times that, and brokers chasing Gulf buyers despite a ban on foreigners. That is not a bug you patch with a nicer posted price. It is what a price on a kidney does: it finds the person who needs rent more than they need a second kidney. The waitlist is real. So is the class of the vendor.

Key assumptions

  • A state-posted price would still sort vendors by poverty rather than by genuine indifference to the organ partial
  • Treating an organ as non-vendible is a legitimate constraint even when it leaves some patients on dialysis untestable

Red team — the strongest counters

Everyone else in the chain is already paid

Surgeons, hospitals, dialysis companies, and pharmaceutical firms take money. The unpaid person is the one who loses the organ. 'Not a commodity' as applied only to the donor is a selective taboo. A state cheque with screening is not a Telegram ad.

Waitlist deaths are also bodies, and they are not volunteering

The vendor at least stands up. The candidate who dies on dialysis did not choose that ending. Istanbul protects one class of the poor (vendors) by leaving another class of the sick on the machine. That is a real trade, not a free dignity.

Sources

  • The Declaration of Istanbul on Organ Trafficking and Transplant Tourism Lancet 2008;372:5–6; 2018 Kidney International update. Commercialism = organ as commodity. Pass-1: declarationofistanbul.org and Lancet exist. P1 checked
  • Iran: How Much Is a Kidney Worth? Iran Open Data, 2026-01. Official gift ~$800–$1,000; unofficial and Telegram prices many times higher; debt as motive; foreign-buyer ads despite ban. Pass-1: page exists. Journalism, not a trial — empirical-moderate for 'what the market looks like,' not for a causal claim that any legal price must look like this. P1 checked

Confidence, decomposed

Logical validity●●●●●
Premise support●●●●○
Representativeness●●●●●
Source quality●●●●○

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

AGAINST · We should pay kidney donors
Logically validP1

Expense help, kidney exchange, and deceased donation are the actual levers — they are not a price on the organ

The third camp is not a secret. US NLDAC and similar programs pay travel and lost wages so donation is not a tax on the generous — that is reimbursement, which NOTA already allows. Kidney paired donation (Roth, Sönmez, Ünver — the matching-market work that won economics a Nobel) moves incompatible pairs without cash for the organ. Deceased donation rose in the US across the 2010s–2020s (OPTN/SRTR: 16,989 deceased donors in 2024). Presumed-consent / opt-out countries vary; Spain's model is organisation as much as law. AGAINST can grant that none of these has zeroed a rich-country list. The steelman is that 'has not yet cleared the list' is not the same finding as 'only a price will.' Held's five-year clearance is an assumption in a supplement, not a trial. If you jump to payment because the other levers are incomplete, you never find out how far follow-up, exchange, and procurement reform go — and you spend the moral capital of transplantation on a market the profession has spent twenty years trying to fence off. The waitlist deaths are an argument for doing the unglamorous work harder, not for converting the donor into a seller.

Key assumptions

  • Expense reimbursement plus exchange plus deceased-donor reform could take a large bite out of the list without an organ price partial
  • Using payment now would crowd out further investment in those levers partial

Red team — the strongest counters

Those levers have had decades and the list is still there

Deceased donation rose and the unique kidney waitlist is still ~95,000. Paired exchange needs a donor already in the family. NLDAC helps people who were going to donate. None of that creates a stranger with a spare kidney. 'Do the unglamorous work harder' is not a number of extra organs.

Held's five-year clearance is an assumption — so is 'the other levers would have been enough'

AGAINST cannot demand a trial of payment and then excuse the unpaid system for never having cleared the list. If incomplete evidence blocks a cheque, it also blocks the claim that reimbursement-plus-exchange is the actual solution.

Sources

Confidence, decomposed

Logical validity●●●●○
Premise support●●●○○
Representativeness●●●●○
Source quality●●●●○

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

AGAINST · We should pay kidney donors
Logically validP1

The family can need the money even when the vendor 'consents'

Zargooshi: 68% of families strongly disagreed with the sale — and the sale happened anyway. Fallah: 68% of paid donors felt pressure from extreme poverty or family, with no evidence of physical force. FOR will say: that is not coercion, that is a reason. AGAINST's reply is that consent under a landlord, a usurer, or a parent who will not eat is the situation a ban is trying not to harvest. A state-posted price large enough to clear a waitlist is large enough to be the household's best bad option. Screening out 'pressure' would mean screening out the people the price is designed to attract. You can write a consent form that a gun did not appear. You cannot write a form that the rent was not due. The living-related unpaid donation already has its own family-pressure problem. Adding cash does not purify that. It nationalises it.

Key assumptions

  • Poverty-pressure is morally closer to coercion than to ordinary labour-market choice untestable
  • A rich-country welfare state would not recreate the same household squeeze around a $45,000 cheque partial

Red team — the strongest counters

Every paid job is a household squeeze by that standard

People mine, fish, and fight wars because rent is due. If poverty-pressure vetoes a kidney price, it vetoes the rest of labour. FOR can grant the squeeze and still say: dialysis is not a less coercive fate for the person on the machine.

Unpaid related donation is the original family-pressure market

Sisters already donate because someone will die. A ban on payment does not abolish that. It keeps the pressure inside the family and off the stranger.

Sources

Confidence, decomposed

Logical validity●●●●●
Premise support●●●●○
Representativeness●●●●○
Source quality●●●●○

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

AGAINST · We should pay kidney donors
Plausible, low testabilityP1

A kidney market does not stay a kidney market

FOR says kidneys only: two of them, dialysis as the alternative, living donation already legal. That is the cleanest organ to monetise, which is why it is the wedge. AGAINST's structural point: there is no principle in 'pay kidney donors' that fails to generalise to any tissue with a waiting list and a living donor. Liver lobes are already donated living; the death rate is higher. The Istanbul definition of commercialism is not kidney-specific. If the FOR mechanism is 'the list is deaths, a cheque is cheap, risk is low,' every organ will hire a Held paper. Iran's Telegram channels already advertise bone marrow and 'any other part.' That is not a slippery-slope cartoon. It is the neighbouring ad. A legal kidney price also has to police export, tourists, and brokers — the thing NOTA and Istanbul exist to make unnecessary. AGAINST can lose the argument that one tightly regulated state monopsony would be a bloodbath in year one, and still hold: institutions leak, and this institution leaks into people. The stop is at expense reimbursement. Crossing it is the claim.

Key assumptions

  • There is no stable political equilibrium at 'kidneys only, state price, citizens only' partial
  • Precedent, not only statute, is what keeps other organs off the menu untestable

Red team — the strongest counters

Lots of body-product rules stay put at one tissue

Plasma is paid in some countries; whole blood often is not. Bone stays unsold where kidney could be paid. A fence at 'paired organ, dialysis alternative, state price, citizens only' is a statute, not a mystery. Slope arguments need a mechanism of collapse, not an adjacent Telegram ad.

Kidney is the cleanest case — that is a reason to stop there, not to refuse the first step

Two kidneys, living donation already legal, a machine as the alternative: if any organ can be priced without becoming 'people as parts,' it is this one. Treating the wedge as automatic slide is how you keep the wedge's victims on dialysis.

Sources

Confidence, decomposed

Logical validity●●●●○
Premise support●●●○○
Representativeness●●●●○
Source quality●●●○○

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

AGAINST · We should pay kidney donors
Plausible, low testabilityP1

Pay for kidneys and you may buy fewer gifts

The Gift Relationship (1970) is the ancestor of this objection: when Britain kept blood unpaid and the US paid some of it, Titmuss argued that price displaces solidarity, brings in worse blood, and does not clearly increase net supply. Kidney is not blood. The analogy is the mechanism. If a sister who would have donated unpaid now waits for a stranger's cheque, or a hospital stops asking families because 'we can buy one,' the living-unrelated column grows while the related column shrinks. Iranian commentators themselves list crowding-out of altruistic donation among the model's defects (see the Mashhad price paper's own caveats). Held's five-year clearance assumes the unpaid stream stays. AGAINST does not need Titmuss to be a randomised trial. It needs the possibility that the net function of a price is substitution, not addition — and that you only find out after you have taught a generation that a kidney is a thing you sell.

Key assumptions

  • Related and unpaid donation would fall by a meaningful amount if a posted price existed testable
  • Blood-market crowding-out is a fair analogue for a paired organ partial

Red team — the strongest counters

The unpaid stream has not cleared the list

If crowding-out is the fear, we already have the experiment: decades of unpaid donation. Net supply is still short. A substitution story that never gets tested because the list is sacred is how you protect a shortage.

Paid plasma did not abolish whole-blood gifts in the US

Two systems coexist. Titmuss predicted ruin. The country still collects unpaid whole blood. The analogue cuts both ways.

Sources

  • The Gift Relationship (Titmuss, 1970) Classic crowding-out and quality argument for paid blood. Pass-1: the book exists. Analogy, not a kidney RCT — tier is not empirical-strong. P1 checked

Confidence, decomposed

Logical validity●●●●○
Premise support●●●○○
Representativeness●●●●○
Source quality●●●○○

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

FOR · We should pay kidney donors
Empirical — moderateP1

People die on waiting lists every year while a spare kidney sits unused

The FOR case starts with a number, not a theory of markets. OPTN/SRTR's 2024 Annual Data Report (Kidney): 3,743 adult candidates were removed from the US waiting list because they died, and 4,901 because they were deemed too sick to transplant. Pretransplant mortality was 4.7 deaths per 100 patient-years. HRSA/organdonor.gov (data as of 30 July 2026) still shows on the order of 95,000 people listed as needing a kidney. The NHS reported hundreds of UK deaths on the kidney list in a recent year; Australia, India, and the Philippines have the same queue in local language — Google Suggest is full of 'waiting list by state' queries worldwide. A transplanted kidney typically lasts years and ends dialysis; five-year survival after kidney transplant is far higher than remaining on dialysis. Living donation is already legal and already done — 7,237 US living donors in 2025 against 16,553 deceased. The shortage is not a mystery of biology. It is a price of zero on a good that is costly to supply. Paying donors is the claim that those deaths are a policy choice, not a fact of nature.

Key assumptions

  • Waitlist death and 'too sick' removal are the right moral numerator, not only transplants performed untestable
  • US and UK waitlist figures stand in for a worldwide shortage rather than a rich-country listing artifact partial
  • Paying living donors would actually raise supply rather than crowd out altruistic gifts one-for-one testable

Red team — the strongest counters

Death on the list is not the same as 'payment would have saved them'

HRSA has flagged ineffective listing parameters; 'too sick' removals are people who may not have been transplantable even with a spare kidney tomorrow. Multi-center listing inflates headcount. Deceased donation is already rising. The numerator is real; the causal leap to a price is not in the ADR.

US and UK lists are listing systems, not the world's missing kidneys

organdonor.gov's ~95k is a rich-country queue of people who reached nephrology. Places with the Suggest noise ('waiting list Tamil Nadu') often have undiagnosed ESRD that never becomes a list. Paying donors in those systems can still miss the people who die unlisted — the Broumand point, pointed at FOR's own worldwide pose.

Sources

  • OPTN/SRTR 2024 Annual Data Report: Kidney SRTR/HRSA ADR. Adult removals 2024: 3,743 death, 4,901 too sick; pretransplant mortality 4.7/100 patient-years. Pass-1: SRTR page and ScienceDirect ADR exist (2026-06). Do not treat multi-center listing totals (~144k) as unique patients — unique kidney waitlist is smaller (~95k on organdonor.gov 2026-07-30). P1 checked
  • Detailed Description of Data (organdonor.gov / HRSA) Patients on the waiting list by organ as of 30 Jul 2026: kidney 95,492. Living donors 2025: 7,237. Pass-1: page exists. P1 checked

Confidence, decomposed

Logical validity●●●●●
Premise support●●●●●
Representativeness●●●●●
Source quality●●●●●

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

FOR · We should pay kidney donors
Empirical — moderateP1

A government cheque is cheap next to a lifetime of dialysis

Held, McCormick, Ojo and Roberts (American Journal of Transplantation, 2016) model a change to US NOTA: the government, not private buyers, pays living donors $45,000 and deceased-donor families $10,000. They estimate about $1.45 million saved per recipient by ending dialysis, plus about $1.3 million for longer healthier life, a social net on the order of $46 billion a year if the list cleared, and about $12 billion a year to taxpayers. Becker and Elías (Journal of Economic Perspectives, 2007) had already argued that a market price for kidneys would be set by the cost of live donation — they put the compensating differential in the low tens of thousands of dollars, not millions — and that supply would become elastic enough to clear. Later Held/McCormick updates raise the living-donor figure (on the order of $77,000 ±50% in 2022 Value in Health work). The FOR steelman does not need the exact dollar. It needs the inequality: dialysis is a machine you rent for the rest of a shorter life; a kidney is a one-time transfer. If you already pay surgeons, hospitals, and dialysis companies, refusing to pay the one person who must lose an organ is not dignity. It is a price control that kills.

Key assumptions

  • A payment in the $45k–$80k band would actually clear a rich-country list in a few years partial
  • Altruistic donation would not collapse by roughly the same number the payment adds testable
  • The payer is the state (or a single insurer), not a bidding war between the rich and the poor testable

Red team — the strongest counters

The $45,000 that 'clears the list' is an input, not a finding

Held et al. assume compensation of $45,000 will elicit adequate supply and end the shortage in five years (their supplement). That is the conclusion dressed as a parameter. Crowd-out of unpaid donors, or a price that has to keep rising, wrecks the $46 billion. Becker–Elías is a model of compensating differentials, not a trial.

Taxpayer savings are US Medicare dialysis arithmetic

The $12 billion figure is a US payer story. A worldwide claim cannot cash a US cost-benefit. In systems that do not already socialise dialysis at US prices, the 'cheque is cheap' inequality changes, and the exploitation objection gets heavier because the vendor is poorer.

Sources

Confidence, decomposed

Logical validity●●●●○
Premise support●●●○○
Representativeness●●●●●
Source quality●●●●●

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

FOR · We should pay kidney donors
Empirical — moderateP1

The medical risk of donating is small next to the risk of waiting

Segev, Muzaale and colleagues (JAMA, 2010) put 90-day surgical mortality at 3.1 per 10,000 live kidney donors. A 2024 JAMA research letter (Massie, Segev et al.) finds that for 2013–2022 the rate had fallen to 0.9 per 10,000 (five deaths). Muzaale et al. (JAMA, 2014): among 96,217 donors, 15-year ESRD was 30.8 per 10,000 versus 3.9 per 10,000 in matched healthy nondonors — a real increase — with estimated lifetime ESRD of 90 per 10,000 donors versus 14 per 10,000 healthy nondonors and 326 per 10,000 in the unscreened general population. Black donors carried more of the absolute risk. That is not 'safe as a haircut.' It is still a different order of magnitude from thousands of waitlist deaths a year. FOR can grant Muzaale in full and still say: we already accept this risk from altruists; paying them does not create the nephrectomy, it stops pretending the only people who may run it are those who can afford unpaid recovery. Long-term follow-up and insurance for donors (the Iranian model's advertised year of coverage; NLDAC-style lost-wage help as a floor) belong inside the payment, not as a substitute for it.

Key assumptions

  • Screened paid donors would have similar perioperative and ESRD risk to today's altruistic donors partial
  • A higher lifetime ESRD rate in donors is an acceptable price for preventing waitlist death untestable

Red team — the strongest counters

Those risk numbers are from unpaid, heavily screened altruists

A price selects for debt. Hideable hypertension, later ESRD, and lost follow-up are the expected shift. Muzaale already shows extra ESRD versus healthy nondonors, concentrated in Black donors. Exporting '0.9 per 10,000' to a paid global pool is a different population.

Lifetime donor ESRD is a harm to a person who was healthy

Waitlist death is a harm to someone already dying. That does not make donor ESRD 'small' from the donor's side. FOR's comparison is social; the vendor lives the residual risk. Mjøen et al. found mortality curves diverging after a decade in Norway — short US series can look fine and still be unfinished.

Sources

Confidence, decomposed

Logical validity●●●●●
Premise support●●●●○
Representativeness●●●●○
Source quality●●●●●

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

FOR · We should pay kidney donors
Empirical — moderateP1

A living kidney lasts longer than a deceased one — payment is how you get more of the better graft

OPTN/SRTR 2023 Annual Data Report: among adult recipients, five-year graft survival for living-donor kidneys was 90.0% at ages 18–34 versus 82.2% for deceased-donor kidneys in the same age band; at 65 and older the gap was 80.2% versus 66.1%. A 2025 UK national cohort (BJS) found living-donor transplantation associated with about 6 percentage points lower five-year graft-failure risk after adjustment (5.61% versus 11.63%). That is why surgeons already prefer a living kidney when one exists. FOR's point is not 'deceased donation is worthless' — deceased volume rose. It is that the unpaid system rations the better graft to people who happen to have a willing relative. A government price is a way to produce living kidneys that are not family kidneys. The waitlist-death argument says there are too few organs. This one says the missing organs are the kind that last.

Key assumptions

  • Paid living donors would produce grafts of similar quality to today's unpaid living donors partial
  • The living-versus-deceased survival gap is mostly the organ, not only healthier recipients who can find a relative partial

Red team — the strongest counters

Healthier people get living kidneys — the gap is selection as much as the organ

Recipients who can find a donor are younger, richer, more adherent. The UK paper adjusts; it does not randomise. Paying strangers does not automatically copy the living-relative graft.

Deceased donation is already the volume lever, and it is rising

16,989 US deceased donors in 2024. If the job is more kidneys, that is the stack that grew. Living payment is a quality argument dressed as a quantity argument, and it still needs the vendor.

Sources

Confidence, decomposed

Logical validity●●●●●
Premise support●●●●○
Representativeness●●●●○
Source quality●●●●●

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

FOR · We should pay kidney donors
Logically validP1

A legal price of zero is still a price — black markets and unpaid recovery already exist

The National Organ Transplant Act (US, 1984) makes it a felony to transfer a human organ for 'valuable consideration' — 42 U.S.C. § 274e — with room for reimbursement of expenses. Most countries copied some version of that ban. The Declaration of Istanbul (Lancet, 2008; updated 2018) names organ trafficking, transplant tourism, and commercialism as the things to prohibit. FOR can grant every horror the Declaration is aimed at: poor vendors, transplant tourists, brokers, bad surgery. The steelman is that a posted public price, paid by the state, with screening and follow-up, is the opposite of that market, not a slide into it. Meanwhile unpaid living donors already 'pay': lost wages, travel, risk, and in some places a year of recovery they cannot afford. NLDAC-style expense help is the third camp (reimburse but do not buy). FOR's reply: if you have already admitted that money may change hands so donation is not a tax on the generous, you are haggling. The claim is the organ price, because that is the lever that can create donors who are not relatives. Altruism did not clear the list. A ban that leaves a queue and a black market is not a moral equilibrium. It is a refusal to name the trade-off.

Key assumptions

  • A legal, posted, state-paid price would shrink trafficking rather than launder it partial
  • Expense reimbursement without a price for the organ cannot clear the list partial

Red team — the strongest counters

A legal channel can launder the black market instead of killing it

Brokers need a hospital more than they need a statute. A posted price plus weak export controls is how tourists and extra-cash deals hide. Istanbul's point was not that bans are pretty. It was that commercialism targets the vulnerable even when it wears a form.

The third camp is not 'haggling' — it is the line the law already drew

NOTA already allows expense reimbursement. NLDAC exists. Calling that haggling assumes the only real lever is the organ price. If lost-wage help and paired exchange are incomplete, the honest move is to finish them, not to treat the remaining deaths as proof that vending is next.

Sources

Confidence, decomposed

Logical validity●●●●●
Premise support●●●○○
Representativeness●●●●●
Source quality●●●●○

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

FOR · We should pay kidney donors
Logically validP1

A government price is how a poor patient gets a kidney — not how a rich one outbids them

Held, McCormick, Ojo and Roberts do not model a eBay for organs. They model NOTA amended so the government pays a living donor a posted sum and the organ enters the same allocation system as today's unpaid grafts. Becker and Elías likewise treat a market price as clearing supply; the egalitarian version puts the payer on the public side so ability to write a personal cheque is not the ranking. Iran's unofficial top-up is what that design is trying not to be. FOR can grant every Istanbul sentence about tourists and brokers and still say: those are what a ban plus a black market produces, and what a monopsony is for. A poor candidate on dialysis is not protected by a law that leaves them on the machine while a rich candidate flies. A single public price, with export banned, is the attempt to make the extra kidney a public good. If you reject that, reject it as unworkable — not as 'selling bodies to the rich,' which is a different proposal.

Key assumptions

  • A state can actually hold a posted price and keep extra cash and tourists out partial
  • Allocation of paid grafts would follow the existing waitlist, not the payer's friends partial

Red team — the strongest counters

Iran ran a government gift and still grew a side payment

KI Reports 2025: unofficial recipient cash typically several times the official gift. A posted monopsony is the brochure. The specimen is the top-up.

Allocation politics will not stay 'the same waitlist'

Once money creates the organ, donors, brokers, and hospitals have a product. Capture is the default of any scarce good the state buys. FOR needs a reason this procurement is cleaner than defence contracting.

Sources

Confidence, decomposed

Logical validity●●●●●
Premise support●●●○○
Representativeness●●●●○
Source quality●●●●○

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

FOR · We should pay kidney donors
Logically validP1

We already pay for plasma, eggs, and trial risk — a kidney is the taboo, not the principle

The United States pays plasma donors at industrial scale and pays people to take experimental drugs. Several countries pay for oocytes. Whole blood is often unpaid; plasma is not. None of those markets is pretty. FOR does not need them to be pretty. It needs the admission that 'you may not sell a part of yourself' is already false. A kidney is riskier than a plasma session and less risky than some trial arms. The Istanbul line treats the paired organ as sacred and the renewable fluid as commerce. That is a stop, not a syllogism. If the objection is exploitation, plasma already has that fight and still runs. If the objection is bodily integrity, so does every paid trial. A state-posted kidney price is closer to those regulated payments than to a back-alley sale — unless you decide in advance that this one tissue is different. That decision needs a reason other than 'we have always banned it.'

Key assumptions

  • Plasma/oocyte/trial payments are morally the same kind of act as a kidney price, not a different category untestable
  • Those markets' harms are acceptable enough that adding a kidney price does not cross a new line partial

Red team — the strongest counters

A renewable fluid is not a paired organ

Plasma replenishes. A kidney does not. Eggs are closer, and they are the fight people already have. Consistency that ignores replenishment is a smash — the same move the solar-geoengineering fight refuses.

Plasma's existence is not a warrant — it is another contested market

You cannot launder a kidney price through a plasma centre. If plasma exploitation is real, it is a reason to fence body markets, not to add the irreversible one.

Sources

  • US plasma compensation is legal and industrial Paid plasma collection is standard US practice (PPTA / FDA licensed centres). Pass-1: the industry exists; this is the consistency specimen, not a finding that plasma markets are harmless. P1 checked

Confidence, decomposed

Logical validity●●●●○
Premise support●●●○○
Representativeness●●●●●
Source quality●●●○○

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.

FOR · We should pay kidney donors
Empirical — weakP1

Iran already runs a legal paid program — the question is design, not metaphysics

Ghods and Savaj (Clinical Journal of the American Society of Nephrology, 2006) described the Iranian model: a compensated, regulated living-unrelated program adopted in 1988; they claimed the renal transplant waiting list was 'completely eliminated' by 1999. Mahdavi-Mazdeh (Kidney International, 2012) is more careful: the model gave most candidates access regardless of class, and named the Achilles heel — no proper long-term donor registry. Iranian clinicians have said in BMJ and later papers that 'it depends how you define waiting list' and that elimination 'has never occurred' in the sense outsiders hear. 2024–2026 reporting (Iran Open Data; KI Reports) describes a small official 'gift' and a much larger unofficial recipient-to-donor payment, plus Telegram markets that look like the black market the regulation was supposed to replace. FOR must own that. The load-bearing fact that survives the contest is narrower: a state can legalise payment, match donors and recipients through an organisation, forbid (on paper) sale to foreigners, and move a large share of transplants onto living unrelated kidneys. That is the existence proof. Whether a rich democracy should copy the unofficial top-up is a design fight — government monopsony, posted price, long-term insurance — not a reason to keep the price at zero.

Key assumptions

  • A legal paid program in one middle-income theocracy tells you something transferable about rich democracies partial
  • The official Iranian 'gift' plus NGO match is the claim, not the unofficial cash topping-up partial

Red team — the strongest counters

Existence of a program is not evidence it should be copied

Smallpox eradication existed; so did Iran's unofficial top-up. Mahdavi-Mazdeh's Achilles heel (no donor registry) and Telegram markets are the specimen. 'We would do it cleaner' is a different country, not a finding about this one.

If the official gift needs a side payment, the posted price is theatre

KI Reports 2025: unofficial recipient payment typically several times the government gift. That is the market FOR says a state monopsony would replace. Iran ran for decades and still has the side payment. Design optimism has a test, and it failed in the only national test.

Sources

Confidence, decomposed

Logical validity●●●●○
Premise support●●●○○
Representativeness●●●●○
Source quality●●●●○

Provenance

Generated by a paired steelman agent (single model family) · red-teamed by an independent adversarial agent · sources Pass-1 spot-checked (existence and rough fit) — framing-fidelity not independently verified. Judged on merit: per the founding rule of this project, AI authorship is disclosed at site level and arguments stand or fall on their content.